# Peptides and UK medicines law Canonical: https://europeanpeptideshop.com/blog/human-medicines-regulations-2012-peptides/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 2 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page The Human Medicines Regulations 2012 are the UK law the MHRA cites when it discusses peptides. Law firm Culbert Ellis gives the starting point: "Peptides are not, as a category, illegal in the UK." ## What do the Human Medicines Regulations 2012 call a medicine? Regulation 2 gives two tests. A substance is a medicinal product if it is presented for disease prevention or treatment in people. It also qualifies if it "may be used by or administered to human beings" with a view to modifying a physiological function or making a diagnosis. ## What do the Human Medicines Regulations 2012 prohibit? Regulation 46 says: the sale, supply or offer of an unauthorised medicinal product is restricted by that provision. Regulation 284 bars any advertisement "likely to lead to the use of a prescription only medicine". ## How does the MHRA apply this to peptides? Case by case. Its official Lynda Scammell said: research-only wording does not decide classification when the presentation indicates a medicinal purpose. This is a summary of the Human Medicines Regulations 2012, not legal advice. See how they apply to [peptide clinics](https://europeanpeptideshop.com/blog/peptide-clinics-uk-mhra/) and to [BPC-157](https://europeanpeptideshop.com/blog/is-bpc-157-legal-in-the-uk/). ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Regulation 2](https://www.legislation.gov.uk/uksi/2012/1916/regulation/2) - [Regulation 46](https://www.legislation.gov.uk/uksi/2012/1916/regulation/46) - [Regulation 284](https://www.legislation.gov.uk/uksi/2012/1916/regulation/284) - [Culbert Ellis, 15 October 2026](https://www.culbertellis.com/news/selling-peptides-in-the-uk-legal-regulatory-and-compliance-considerations) - [Pharmacy Business, 7 April 2026](https://www.pharmacy.biz/mhra-peptide-injections-investigation-uk/) ## More articles Comparisons · 3 min read ## [GLP-1 medicines and research materials](https://europeanpeptideshop.com/blog/glp-1-peptides-vs-research-peptides/) Why receptor targets, peptide identity, study evidence and the status of a supplied research material are separate questions. 8 November 2026 Research news · 2 min read ## [Australia's Synedica peptide warning](https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/) Australian testing found Synedica peptide products contained no TB-500 and less retatrutide than labelled. The TGA has told Australians to discard them. 8 November 2026 Research news · 3 min read ## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/) Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans. 8 November 2026